Furthermore, there is but one Food and Drug Administration (FDA)-approved drug for stroke, namely, tissue plasminogen activator (tPA), which presents significant limitations: a time-constrained therapeutic window (the drug must be given within 4.5 h from stroke onset), and adverse side effects associated with delayed treatment of the drug, most notably hemorrhagic transformation (HT) [2]. Here, PLAT is linked to hematocrit.